Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen NeuMoDx Human Adenovirus Assay Receives CE Mark

NEW YORK – Qiagen said on Thursday that its NeuMoDx HAdV Quant Assay for the identification and quantification of human adenovirus DNA has received CE-IVD certification.

Qiagen developed the assay in partnership with Sentinel Diagnostics, and the test adds to the current NeuMoDx transplant assay menu that already includes CE-marked tests for cytomegalovirus, Epstein-Barr virus, and BK virus viral load monitoring for the management of immunocompromised patients, such as those who have undergone organ transplantation.

All of these assays use Qiagen's automated, three-step NeuMoDx workflow that extracts DNA from blood or urine to isolate target nucleic acids followed by real-time PCR to target conserved sequences in the genomes of target viruses.

The new assay is also the 15th overall available on the NeuMoDx 96 and 288 Molecular Systems, which enables true random access of Qiagen-developed tests as well as laboratory-developed tests.

Qiagen acquired the remaining stake in NeuMoDx in September 2020 after having acquired a minority stake in the Ann Arbor, Michigan-based diagnostic developer in 2018 as part of a test menu development deal.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.